Literature DB >> 9509290

New atypical antipsychotics. Experience and utility in the elderly.

R A Sweet1, B G Pollock.   

Abstract

The atypical antipsychotics are a new class of agents with great promise for use in the elderly because of their reduced propensity to cause acute extrapyramidal adverse effects. Treatment of older patients with these agents, however, needs to take into consideration age-related changes in pharmacokinetics and the risks of drug-drug interactions. Additionally, current evidence of their efficacy in late-life psychoses is derived largely from case series and from the extrapolation of results obtained in studies of younger patients with schizophrenia. Controlled clinical studies of atypical antipsychotics in elderly patients are urgently needed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9509290     DOI: 10.2165/00002512-199812020-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  86 in total

1.  Influence of patient-related variables on clozapine plasma levels.

Authors:  C Haring; W W Fleischhacker; P Schett; C Humpel; C Barnas; A Saria
Journal:  Am J Psychiatry       Date:  1990-11       Impact factor: 18.112

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Seroquel and cognitive improvement in patients with schizophrenia.

Authors:  E Stip; I Lussier; M Babai; J L Fabian; C Link
Journal:  Biol Psychiatry       Date:  1996-09-01       Impact factor: 13.382

4.  The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.

Authors:  H Y Meltzer; S Matsubara; J C Lee
Journal:  Psychopharmacol Bull       Date:  1989

5.  Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity.

Authors:  J M Swearer; D A Drachman; B F O'Donnell; A L Mitchell
Journal:  J Am Geriatr Soc       Date:  1988-09       Impact factor: 5.562

Review 6.  Education and the prevalence of dementia and Alzheimer's disease.

Authors:  R Katzman
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

7.  Influence of age, frailty and liver function on the pharmacokinetics of brofaromine.

Authors:  J Zeeh; L Fuchs; W Bergmann; K H Antonin; F Degel; P Bieck; D Platt
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

8.  Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.

Authors:  B G Pollock; J M Perel; L P Altieri; M Kirshner; A L Fasiczka; P R Houck; C F Reynolds
Journal:  Psychopharmacol Bull       Date:  1992

9.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

Authors:  D V Jeste; M P Caligiuri; J S Paulsen; R K Heaton; J P Lacro; M J Harris; A Bailey; R L Fell; L A McAdams
Journal:  Arch Gen Psychiatry       Date:  1995-09

10.  Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

Authors:  B J Ring; J Catlow; T J Lindsay; T Gillespie; L K Roskos; B J Cerimele; S P Swanson; M A Hamman; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

View more
  15 in total

Review 1.  Late-onset schizophrenia: epidemiology, diagnosis, management and outcomes.

Authors:  P A Wynn Owen; D J Castle
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 2.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.

Authors:  N Bhana; C M Spencer
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 4.  Antipsychotic treatment for late-life schizophrenia.

Authors:  Jeremy A Sable; Dilip V Jeste
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

5.  Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.

Authors:  Janitza L Montalvo-Ortiz; Daniel W Fisher; Guadalupe Rodríguez; Deyu Fang; John G Csernansky; Hongxin Dong
Journal:  Psychopharmacology (Berl)       Date:  2017-04-18       Impact factor: 4.530

Review 6.  Prescribing of psychotropics in the elderly: why is it so often inappropriate?

Authors:  Jane R Mort; Rajender R Aparasu
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Quality of drug prescribing in elderly people in nursing homes and special care units for dementia: a cross-sectional computerized pharmacy register analysis.

Authors:  Jonny Olsson; Asa Bergman; Anders Carlsten; Thimothy Oké; Cecilia Bernsten; Ingrid K Schmidt; Johan Fastbom
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 8.  Adverse effects of clozapine in older patients: epidemiology, prevention and management.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 9.  Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.

Authors:  M R Caligiuri; D V Jeste; J P Lacro
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

10.  Impact of Antipsychotics on Geriatric Patients: Efficacy, Dosing, and Compliance.

Authors:  Gerald A. Maguire
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.